CHINA PHARMA HOLDINGS, INC. Contract with Customer, Asset, Allowance for Credit Loss, Current
CHINA PHARMA HOLDINGS, INC. (CPHI) had Contract with Customer, Asset, Allowance for Credit Loss, Current of $4.03 thousand as of 2025-12-31, per its 10-K filed 2026-04-01.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent · last filed 2026-04-01
- 2025-12-31: Contract with Customer, Asset, Allowance for Credit Loss, Current $4.03K.
- 2024-12-31: Contract with Customer, Asset, Allowance for Credit Loss, Current $5.07K.
| Period end | Contract with Customer, Asset, Allowance for Credit Loss, Current |
|---|---|
| 2025-12-31 | $4.03K 10-K · filed 2026-04-01 |
| 2024-12-31 | $5.07K 10-K · filed 2026-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |